Biovica International B
Develops blood-based biomarker assays for cancer therapy monitoring.
BIOVIC | ST
Overview
Corporate Details
- ISIN(s):
- SE0008613681 (+3 more)
- LEI:
- 549300VADE1VRR555N78
- Country:
- Sweden
- Address:
- Dag Hammarskjölds väg 54B, 752 37 Uppsala
- Website:
- https://biovica.com/
Description
Biovica International is a biotechnology company that develops and commercializes blood-based biomarker assays to improve cancer therapy monitoring. The company's primary product is the DiviTum® TKa Test, a blood test that measures cell proliferation by analyzing thymidine kinase activity. This assay is designed to monitor disease progression and evaluate treatment efficacy for patients with solid tumors, with a particular focus on metastatic breast cancer. The test provides oncologists with critical data to predict patient outcomes and make more informed therapeutic decisions, especially for those on modern treatments like CDK4/6 inhibitors. The technology is utilized in both clinical settings and pharmaceutical research to enhance cancer care.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Biovica International B filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Biovica International B
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Biovica International B via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
